Immatics (NASDAQ:IMTX) to Post FY2024 Earnings of ($1.11) Per Share, Chardan Capital Forecasts

Immatics (NASDAQ:IMTX) – Chardan Capital issued their FY2024 earnings per share (EPS) estimates for shares of Immatics in a research note issued on Monday, July 1st. Chardan Capital analyst Y. Livshits expects that the company will post earnings per share of ($1.11) for the year. The consensus estimate for Immatics’ current full-year earnings is ($1.29) per share. Chardan Capital also issued estimates for Immatics’ FY2025 earnings at ($1.15) EPS.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings results on Tuesday, May 14th. The company reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.70. Immatics had a negative return on equity of 29.36% and a negative net margin of 107.80%. The business had revenue of $32.87 million during the quarter, compared to analysts’ expectations of $17.76 million.

Separately, Mizuho boosted their price objective on Immatics from $14.00 to $16.00 and gave the stock a “buy” rating in a report on Thursday, May 16th.

Immatics Stock Performance

Immatics stock opened at $11.82 on Thursday. Immatics has a 52 week low of $7.15 and a 52 week high of $13.77. The stock has a market capitalization of $1.00 billion, a P/E ratio of -11.15 and a beta of 0.75. The stock has a 50-day simple moving average of $11.60 and a 200 day simple moving average of $11.38.

Institutional Investors Weigh In On Immatics

A number of institutional investors have recently made changes to their positions in IMTX. Trexquant Investment LP bought a new stake in shares of Immatics during the third quarter worth approximately $498,000. Adage Capital Partners GP L.L.C. acquired a new position in Immatics during the third quarter valued at approximately $3,781,000. Walleye Capital LLC acquired a new position in Immatics during the third quarter valued at approximately $1,318,000. Hudson Bay Capital Management LP raised its position in Immatics by 8.1% during the third quarter. Hudson Bay Capital Management LP now owns 400,580 shares of the company’s stock valued at $4,639,000 after purchasing an additional 30,000 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its stake in shares of Immatics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 11,501 shares of the company’s stock worth $121,000 after buying an additional 2,916 shares during the last quarter. Institutional investors own 64.41% of the company’s stock.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.